Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

40
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
40
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

16
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

27
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
27
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

65
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
65
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

14
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
14
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

24
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
24

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interictal serum L-kynurenine and PACAP-38 levels in relation to allodynia and migraine subtypes.

Headache·2026
Same author

Giant mass-like ankle pannus in rheumatoid arthritis.

Scandinavian journal of rheumatology·2026
Same author

Preptin, PPARγ, and NLRP3 as inflammatory biomarkers in pediatric obesity - a pilot study.

BMC pediatrics·2025
Same author

Determination of Biotin Interference in Pediatric Obesity Related ELISA Research Kits Biotin Interference in Manual ELISA Kits.

Journal of clinical laboratory analysis·2025
Same author

SCUBE-1 Levels and Their Relationship with Endothelial Dysfunction in Obstructive Sleep Apnea Syndrome Patients.

Nature and science of sleep·2025
Same author

Low Frequency of HLA-B27 in Ankylosing Spondylitis Patients from Turkey: Insights from the Thrace Region.

Medical science monitor : international medical journal of experimental and clinical research·2025

Related Experiment Video

Updated: Aug 7, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.0K

Cardiovascular disease risk prediction in scleroderma.

Aliye Çelikkol1, Rıdvan Mercan2, Savaş Güzel1

  • 1Tekirdağ Namık Kemal University, Faculty of Medicine, Department of Medical Biochemistry - Tekirdağ, Turkey.

Revista Da Associacao Medica Brasileira (1992)
|March 8, 2023
PubMed
Summary

Cardiac myosin-binding protein-C and trimethylamine N-oxide show promise as noninvasive biomarkers for predicting cardiovascular disease risk in scleroderma patients. These markers can help distinguish between low and high-moderate risk groups using the Systematic COronary Risk Evaluation 2 model.

More Related Videos

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

4.0K
Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
06:04

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome

Published on: September 27, 2024

983

Related Experiment Videos

Last Updated: Aug 7, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.0K
Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

4.0K
Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
06:04

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome

Published on: September 27, 2024

983

Area of Science:

  • Cardiology
  • Rheumatology
  • Biomarker Discovery

Background:

  • Cardiovascular disease (CVD) poses a significant risk for patients with scleroderma.
  • Accurate CVD risk prediction is crucial for timely intervention and management in scleroderma.
  • Current risk assessment models may benefit from novel, noninvasive biomarkers.

Purpose of the Study:

  • To investigate the association between cardiac myosin-binding protein-C (cMyC-C), sensitive troponin T (sTnT), and trimethylamine N-oxide (TMAO) with CVD risk in scleroderma.
  • To evaluate the utility of these biomarkers in conjunction with the Systematic COronary Risk Evaluation 2 (SCORE 2) model.

Main Methods:

  • A cohort of 52 women with scleroderma and 38 healthy controls were assessed.
  • Levels of cMyC-C, sTnT, and TMAO were quantified using commercial ELISA kits.
  • Patients were categorized into low and high-moderate CVD risk groups based on the SCORE 2 model.

Main Results:

  • Scleroderma patients exhibited significantly higher levels of cMyC-C and TMAO compared to controls (p<0.001 for both).
  • sTnT levels did not differ significantly between scleroderma patients and controls (p=0.274).
  • TMAO and cMyC-C demonstrated good discriminatory ability for high-moderate CVD risk (sensitivity 76% and 75%, specificity 86% and 83%, respectively).
  • Elevated TMAO (≥10.28 ng/mL) and cMyC-C (≥8.29 ng/mL) were independently associated with significantly higher SCORE 2 risk (OR: 15.00 and 11.00, respectively).

Conclusions:

  • cMyC-C and TMAO are potential noninvasive biomarkers for assessing CVD risk in scleroderma.
  • These biomarkers can aid in differentiating between low and high-moderate CVD risk strata within the SCORE 2 framework.
  • Further research is warranted to integrate these findings into clinical practice for improved scleroderma patient management.